The consensus among analysts is that Chiasma, Inc. (CHMA) is a Buy stock at the moment, with a recommendation rating of 2. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 4 have rated it as a Hold, with 4 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.38.
Chiasma, Inc. (NASDAQ:CHMA) trade information
Despite being -7.57% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Friday, Jun 26 when the CHMA stock price touched $7.75-2 or saw a rise of 27.48%. Year-to-date, Chiasma, Inc. shares have moved 13.31%, while the 5-day performance has seen it change -19.83%. Over the past 30 days, the shares of Chiasma, Inc. (NASDAQ:CHMA) have changed -10.08%. Short interest in the company has seen 1.35 Million shares shorted with days to cover at 0.
Chiasma, Inc. (CHMA) estimates and forecasts
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -51.6% over the past 5 years. Earnings growth for 2020 is a modest +17.1% while over the next 5 years, the company’s earnings are expected to increase by 46.3%.
Chiasma, Inc. (NASDAQ:CHMA)’s Major holders
Insiders own 4.52% of the company shares, while shares held by institutions stand at 82.54% with a share float percentage of 86.45%. Investors are also buoyed by the number of investors in a company, with Chiasma, Inc. having a total of 122 institutions that hold shares in the company. The top two institutional holders are MPM Asset Management, LLC with over 5.74 Million shares worth more than $20.94 Million. As of March 30, 2020, MPM Asset Management, LLC held 13.57% of shares outstanding.
The other major institutional holder is Adage Capital Partners GP L.L.C., with the holding of over 2.9 Million shares as of March 30, 2020. The firm’s total holdings are worth over $10.59 Million and represent 6.86% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Fidelity Select Portfolios – Biotechnology and Vanguard Total Stock Market Index Fund. As of March 30, 2020, the former fund manager holds about 3.85% shares in the company for having 1625699 shares of worth $5.93 Million while later fund manager owns 1.04 Million shares of worth $3.79 Million as of March 30, 2020, which makes it owner of about 2.46% of company’s outstanding stock.